Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Codexis reports strong 2022 performance, eyes growth in Life Sciences

Codexis made significant progress in 2022, focusing on high-value programs and enhancing technical capabilities.
While facing challenges in managing expenses and revenue variability, the company is well-positioned with a strong cash position and growth opportunities.
Strategic collaborations and revenue diversification efforts position Codexis for sustainable growth and value creation in the future.

Codexis navigates revenue challenges, eyes growth through strategic partnerships

Codexis is strategically focusing on the ECO Synthesis platform and pharmaceutical manufacturing business for revenue growth and positive cash flow by 2026.
While facing challenges such as impairments on investments and revenue timing, the company is leveraging opportunities through partnerships and operational improvements.
The company's financial discipline, strong balance sheet, and key collaborations position it well for future growth and success in the pharmaceutical manufacturing sector.
With ongoing negotiations and advancements in technology, Codexis is poised for continued progress and innovation in the enzymatic solutions market.

Codexis reports robust Q4 performance, eyes growth through strategic partnerships

Codexis delivered a strong performance in Q4 2023, driven by strategic decisions, partnerships, and financial results showcasing growth potential.
The company's focus on expanding the ECO Synthesis platform and pharmaceutical manufacturing bodes well for sustained revenue growth.
While facing challenges in scaling operations and managing expenses, Codexis is well-positioned to capitalize on market opportunities and drive innovation.

Codexis projects 10% revenue growth, advances in RNA synthesis

Codexis is poised for growth in 2024, with a focus on revenue expansion, product innovation, and strategic partnerships to drive market success.
The company's strong performance in supplying enzymes for various programs underscores its market leadership and technological capabilities.
While facing challenges in diversifying its customer base and sustaining growth, Codexis is leveraging its strengths in technology and innovation to seize emerging opportunities.

Codexis reports Q3 revenue growth, eyes profitability amid strategic investments

Codexis navigates Q3 2024 with revenue growth in pharma manufacturing and strategic investments for future profitability.
Despite a net loss, the company maintains financial stability with a strong cash position and a focus on enhancing capabilities.
Challenges lie in achieving profitability by 2026, managing divestiture impacts, and optimizing gross margins amid operational changes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference

Apple

Aehr Test Systems

Celsius Holdings

Cisco Systems

Chevron

Enphase Energy

Intrepid Potash

Merck

Microsoft

Trillium Therapeutics

Verizon

Walmart

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through the week.

Week 52 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Precigen

Verve Therapeutics

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

3 Synthetic Biology Stocks in Focus With Strong Potential

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR). RT-qPCR is currently used widely for viral diagnostic tests, including SARS-CoV-2 nucleic acid amplification tests. This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples.

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming virtual investment conferences.

Codexis to Participate in Upcoming Virtual Healthcare Conferences

Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript

Record Quarterly Total Revenue, Product Revenue and Product Gross Margin Reiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M

Codexis Reports Third Quarter 2021 Financial Results

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report Third Quarter 2021 Financial Results on November 4

Codexis is leveraging its core technology to create more effective life science tools.

Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients (APIs), and RC2 Pharma Connect, LLC, a U.S.-based leading pharmaceutical manufacturing representative, to license and manufacture for internal use a Codexis' proprietary enzyme used in the manufacturing process for sitagliptin, a leading API in the treatment of diabetes. Under the agreement, Almelo will be responsible for the development, scale-up, and establishment of a commercial manufacturing process for sitagliptin incorporating Codexis' proprietary enzyme technology. Upon completion, the enzyme's manufacturing will be established at Almelo's API manufacturing site to enable further cost reduction. RC2's role in the collaboration will be to leverage its relationships with global drug product partners to establish downstream supply channels for the future generic sitagliptin market.

Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India

If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's What Could Help Codexis (CDXS) Maintain Its Recent Price Strength

Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?

Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet.

Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck's JANUVIA® and one of the active ingredients in Merck's JANUMET®.

Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

Orders Support Company's Recently Increased 2021 Guidance Orders Support Company's Recently Increased 2021 Guidance

Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and beverage industry, announced that the companies have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsec's newest natural hop acid.

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver® platform technology transfer with Novartis Pharma AG (“Novartis”) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver® to develop novel performance enzymes for use in the manufacture of pharmaceutical products.

Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader

CM Life Sciences II Inc - Unit

Iridium Communications

Surface Oncology Inc

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

ARK Investment Leans Into Biotech and Telecom Holdings

REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.

Codexis Earns Milestone Payment from GlaxoSmithKline

Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?

Codexis Inc (NASDAQ: CDXS) raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclosed pharmaceutical company. Now, the Company expects 2021 total revenues in the range of $89 million to $93 million, up from previous guidance of $82 million to $85 million, higher than the $83.7 million consensus.

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

REDWOOD CITY, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company. The majority of this order was not included in Codexis' prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million. Codexis is also increasing its 2021 guidance for product revenue to a range of $45 million to $48 million, up from previous guidance of $36 million to $39 million. In addition, the Company is raising 2021 guidance for product gross margin to a range of 60% to 64%, up from previous guidance of 54% to 58%.

News for Codexis Stock (CDXS)